TransMedics Group (NASDAQ:TMDX – Get Free Report) released its earnings results on Monday. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16), Briefing.com reports. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.12) EPS. TransMedics Group updated its FY 2024 guidance to EPS.
TransMedics Group Price Performance
Shares of NASDAQ:TMDX opened at $89.67 on Tuesday. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of 3,156.00 and a beta of 1.99. The business has a 50-day simple moving average of $147.58 and a two-hundred day simple moving average of $140.19. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37.
Insider Activity
In other news, insider Anil P. Ranganath sold 4,289 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the transaction, the insider now directly owns 8,893 shares of the company’s stock, valued at $1,353,514.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the transaction, the insider now directly owns 8,893 shares in the company, valued at approximately $1,353,514.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,205 shares of company stock valued at $9,981,907 in the last 90 days. 7.00% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on TransMedics Group
TransMedics Group Company Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Recommended Stories
- Five stocks we like better than TransMedics Group
- How to Invest in Insurance Companies: A GuideĀ
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks Reporting Kitchen Sink Quarters to Usher in a Turnaround
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.